Andrea Bertotti

Prioritization of cancer therapeutic targets using CRISPR–Cas9 screens

Fiona M. Behan, Francesco Iorio, Gabriele Picco et al. · Nature · 2019 · 1.3K citations · Full text

Crispr–cas9 Screens, Gene Editing, Genome Editing +4

Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial

Andrea Sartore‐Bianchi, Livio Trusolino, Cosimo Martino et al. · The Lancet Oncology · 2016 · 984 citations · Full text

Oncology, Medicine, Pathology +5

A Molecularly Annotated Platform of Patient-Derived Xenografts (“Xenopatients”) Identifies HER2 as an Effective Therapeutic Target in Cetuximab-Resistant Colorectal Cancer

Andrea Bertotti, Giorgia Migliardi, Francesco Galimi et al. · Cancer Discovery · 2011 · 938 citations · Full text

Amplification of the <i>MET</i> Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer

Alberto Bardelli, Simona Corso, Andrea Bertotti et al. · Cancer Discovery · 2013 · 654 citations · Full text

Engineering, Pathology, Cancer Biology +17

Stromal contribution to the colorectal cancer transcriptome

Claudio Isella, Andrea Terrasi, Sara E. Bellomo et al. · Nature Genetics · 2015 · 645 citations · Full text

Pathology, Colorectal Cancer, Colorectal Cancer Transcriptome +6